دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Stabilizing the neural barrier – A novel approach in pain therapy
doi : 10.1016/j.pharmthera.2023.108484
Volume 249, September 2023, 108484
Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines
Jian-Li Chen 1 , Xuan Wu 1 , Dan Yin, Xiao-Hui Jia, Xu Chen, Ze-Yun Gu, Xiao-Ming Zhu
doi : 10.1016/j.pharmthera.2023.108485
Volume 249, September 2023, 108485
An erythrocyte-centric view on the MFSD2B sphingosine-1-phosphate transporter
Shahrooz Ghaderi, Bodo Levkau
doi : 10.1016/j.pharmthera.2023.108483
Volume 249, September 2023, 108483
Targeting PCSK9 to tackle cardiovascular disease
Sandra Hummelgaard a , Joachim Pold Vilstrup b , Camilla Gustafsen b , Simon Glerup a,b , Kathrin Weyer
doi : 10.1016/j.pharmthera.2023.108480
Volume 249, September 2023, 108480
Retina and RPE lipid profile changes linked with ABCA4 associated Stargardt's maculopathy
Mitra Farnoodian a , Devika Bose a , Francesca Barone a , Luke Mathew Nelson a , Marisa Boyle a , Bokkyoo Jun b , Khanh Do c , William Gordon b , Marie-Audrey Kautzmann Guerin b , Rasangi Perera b , Jeff X. Ji b , Tiziana Cogliati d , Ruchi Sharma a , Brian P. Brooks e , Nicolas G. Bazan b , Kapil Bharti
doi : 10.1016/j.pharmthera.2023.108482
Volume 249, September 2023, 108482
The shared role of cholesterol in neuronal and peripheral inflammation
Scott B. Hansen a,b,?, Hao Wang c
doi : 10.1016/j.pharmthera.2023.108486
Volume 249, September 2023, 108486
Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review
Jinyun Dong a,b,?, Li Yuan a,b , Can Hu a,b , Xiangdong Cheng a,b,?, Jiang-Jiang Qin
doi : 10.1016/j.pharmthera.2023.108488
Volume 249, September 2023, 108488
Potassium homeostasis – Physiology and pharmacology in a clinical context
Ralph Kettritz a,b,?, Johannes Loffing
doi : 10.1016/j.pharmthera.2023.108489
Volume 249, September 2023, 108489
Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?
Martina Catalano a , Giuseppe Procopio b , Pierangela Sepe b , Matteo Santoni c , Francesco Sessa d , Donata Villari e , Gabriella Nesi f , Giandomenico Roviello
doi : 10.1016/j.pharmthera.2023.108499
Volume 249, September 2023, 108499
Vasospastic angina: Past, present, and future
Zuowen He a,b,1 , Xin Xu b,1 , Qu Zhao b , Hu Ding a,b , Dao Wen Wang a,b,?
doi : 10.1016/j.pharmthera.2023.108500
Volume 249, September 2023, 108500
Pathophysiological mechanisms of complications associated with propionic acidemia
Hannah Marchuk a,1 , You Wang b,c,1 , Zachary Alec Ladd d , Xiaoxin Chen d,e,f,?, Guo-Fang Zhang
doi : 10.1016/j.pharmthera.2023.108501
Volume 249, September 2023, 108501
Preface to the Special Issue
Darryl C. Zeldin a,?, Kenneth Honn b , Caryn Volpe
doi : 10.1016/j.pharmthera.2023.108497
Volume 249, September 2023, 108497
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy
Aqsa Ashfaq a , Myriam Meineck b , Andrea Pautz a , Ebru Arioglu-Inan c , Julia Weinmann-Menke b , Martin C. Michel
doi : 10.1016/j.pharmthera.2023.108503
Volume 249, September 2023, 108503
Adenosine receptor signalling as a driver of pulmonary fibrosis
Emily Cash a,b , Amanda T. Goodwin a,b , Amanda L. Tatler a,b,?
doi : 10.1016/j.pharmthera.2023.108504
Volume 249, September 2023, 108504
The Triple Crown: NO, CO, and H2S in cancer cell biology
Palak P. Oza a , Khosrow Kashfi a,b,?
doi : 10.1016/j.pharmthera.2023.108502
Volume 249, September 2023, 108502
Pharmacological interventions targeting α-synuclein aggregation triggered REM sleep behavior disorder and early development of Parkinson's disease
Lida Du a,b,?, Xiaoli He c , Xiaonuo Fan d , Xiaoya Wei e , Linhao Xu b,f , Tuo Liang b,g , Chunbo Wang a , Ya Ke b , Wing-ho Yung b,h,??
doi : 10.1016/j.pharmthera.2023.108498
Volume 249, September 2023, 108498
GABAergic modulation of sleep-wake states
Yo Oishi a,b,1 , Yuki C. Saito a,b,1 , Takeshi Sakurai
doi : 10.1016/j.pharmthera.2023.108505
Volume 249, September 2023, 108505
